


TNG-462

## Chemical Properties

CAS No. : 2760483-96-1  
 Formula: C<sub>28</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub>S  
 Molecular Weight: 520.69  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



## Biological Description

Description	TNG-462 is a potent and selective PRMT5 inhibitor with antitumor activity and oral activity, primarily for the treatment of methylthioadenosine phosphorylase (MTAP)-deficient and/or methylthioadenosine (MTA)-accumulating cancers (e.g., non-small-cell lung cancer, pancreatic cancer, bladder cancer, and hematologic malignancies).
Targets(IC50)	Histone Methyltransferase
In vitro	Methods: Tumor cells (NSCLC, PDAC, bladder, hematological malignancies) deficient in MTAP were treated with TNG-462 (0-1 $\mu$ M) and cell viability was measured. Results: TNG-462 selectively inhibited cell viability with an IC <sub>50</sub> value of less than 1 $\mu$ M. [2]
In vivo	Methods: TNG-462 (40 mg twice a day; 100 mg/kg twice a day, orally, for 21 days) was used to treat a xenograft mouse model derived from a MTAP-deficient cell line and observe tumor growth in vivo. Results: TNG-462 inhibited tumor growth in mice and showed anti-tumor activity. [2]

## Solubility Information

Solubility	DMSO: 80 mg/mL (153.64 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.34 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.9205 mL	9.6026 mL	19.2053 mL
5 mM	0.3841 mL	1.9205 mL	3.8411 mL
10 mM	0.1921 mL	0.9603 mL	1.9205 mL
50 mM	0.0384 mL	0.1921 mL	0.3841 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kevin M Cottrell, et al. Piperidin-1-yl-n-pyridine-3-yl-2-oxoacetamide derivatives useful for the treatment of mta-deficient and/or mta-accumulating cancers. Patent WO2022026892A1.

Briggs K, et al. TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors[J]. Cancer Research, 2023, 83(7\_Supplement): 4970-4970.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481